FDA-Approved Clot Removal Devices Show Promise for Stroke Patients
Stony Brook, N.Y. - Specialists at Stony Brook Medicine’s Cerebrovascular and Stroke Center (CVC) are treating patients with a new generation of blood clot removal devices that show promise in successfully revascularizing stroke patients, including those with large vessel blockages. The Solitaire Flow Restoration Device and the Trevo device, approved by Food and Drug Administration (FDA) in 2012 to treat stroke caused by the sudden obstruction of a brain blood vessel (acute ischemic stroke) showed improved results over a previous standard and first generation clot-removal device in clinical trials.
“We have had excellent outcomes using these new devices,” said David Fiorella, M.D., Ph.D., a Professor of Clinical Neurological Surgery and Radiology at Stony Brook University School of Medicine and Co-Director of the CVC. “In acute ischemic stroke, ‘time is brain,’ and in some cases just minutes matter. These new devices enable us to quickly restore blood flow and retrieve the clot in most patients,” said Dr. Fiorella, who has performed some 30 procedures on stroke patients using the new devices.
“These blot clot removal devices are an important new component of our armamentarium against stroke” said Henry Woo, MD, Professor of Neurological Surgery and Radiology and Co-Director of the CVC, who has also used both devices in patient procedures. Continue>
Posted in: News Briefs | October 20, 2014
Posted in: News Briefs | September 17, 2014
Posted in: News Briefs | September 5, 2014